Metabolic reprogramming of the tumour microenvironment

FEBS Journal

Volumn 282, Issue 20, 2015, Pages 3892-3898

  Xing, Yazhi ^a   Zhao, Shimin ^b   Zhou, Binhua P ^c   Mi, Jun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Aerobic glycolysis; cancer associated fibroblast; epigenetic regulation; metabolic reprogramming; metabolites shuttling; oxidative phosphorylation; tumor progression; tumour microenvironment; tumour associated macrophage; Warburg effect

Indexed keywords

2 HYDROXYGLUTARIC ACID; ADENOSINE TRIPHOSPHATE; CAVEOLIN 1; CHEMOKINE RECEPTOR CXCR4; CONNECTIVE TISSUE GROWTH FACTOR; CXCL14 CHEMOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; ISOCITRATE DEHYDROGENASE; LACTIC ACID; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 3; NERVE GROWTH FACTOR; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RETINOBLASTOMA PROTEIN; SCATTER FACTOR; SOMATOMEDIN; STROMAL CELL DERIVED FACTOR 1; UNINDEXED DRUG; VASCULOTROPIN A; WNT PROTEIN;

AEROBIC GLYCOLYSIS; CANCER ASSOCIATED ENDOTHELIAL CELL; CANCER ASSOCIATED FIBROBLAST; CANCER ASSOCIATED PERICYTE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; ENZYME ACTIVATION; EPIGENETICS; FIBROBLAST; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; INFLAMMATORY CELL; MACROPHAGE ACTIVATION; METASTASIS; MITOCHONDRION; MONOCYTE; NONHUMAN; NUCLEAR REPROGRAMMING; ONCOGENE; ONCOGENE C MYC; ONCOGENE RAS; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; ANIMAL; BIOLOGICAL MODEL; ENERGY METABOLISM; IMMUNOLOGY; MACROPHAGE; METABOLISM; NEOPLASM; PATHOLOGY; PERICYTE; SECONDARY METABOLISM;

ANIMALS; CELL PROLIFERATION; CELLULAR REPROGRAMMING; ENERGY METABOLISM; FIBROBLASTS; HUMANS; MACROPHAGES; MODELS, BIOLOGICAL; NEOPLASMS; PERICYTES; SECONDARY METABOLISM; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84944273587     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13402     Document Type: Review

References (20)

1. Hanahan D, &, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674.
2. Zhang D, Wang Y, Shi Z, Liu J, Sun P, Hou X, Zhang J, Zhao S, Zhou BP, &, Mi J, (2015) Metabolic reprogramming of cancer-associated fibroblasts by IDH3a downregulation. Cell Rep. 10, 1335-1348.
3. Jones RG, &, Thompson CB, (2009) Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23, 537-548.
4. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, et al,. (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765.
5. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, &, Hwang PM, (2006) p53 regulates mitochondrial respiration. Science 312, 1650-1653.
6. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, &, Thompson CB, (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67, 6745-6752.
7. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL, &, Thompson CB, (2005) The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24, 4165-4173.
8. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al,. (2010) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465, 966.
9. Simon S, Roy D, &, Schindler M, (1994) Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci USA 91, 1128-1132.
10. Simon SM, &, Schindler M, (1994) Cell biological mechanisms of multidrug resistance in tumors. Proc Natl Acad Sci USA 91, 3497-3504.
11. Raghunand N, He X, van Sluis R, Mahoney B, Baggett B, Taylor CW, Paine-Murrieta G, Roe D, Bhujwalla ZM, &, Gillies RJ, (1999) Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80, 1005-1011.
12. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, &, Locati M, (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25, 677-686.
13. Pello OM, De Pizzol M, Mirolo M, Soucek L, Zammataro L, Amabile A, Doni A, Nebuloni M, Swigart LB, Evan GI, et al,. (2012) Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 119, 411-421.
14. Murdoch C, Giannoudis A, &, Lewis CE, (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104, 2224-2234.
15. Ji RC, (2006) Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev 25, 677-694.
16. Mantovani A, Sozzani S, Locati M, Allavena P, &, Sica A, (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23, 549-555.
17. Zhu L, Zhao Q, Yang T, Ding W, &, Zhao Y, (2015) Cellular metabolism and macrophage functional polarization. Int Rev Immunol 34, 82-100.
18. Munder M, Eichmann K, Moran JM, Centeno F, Soler G, &, Modolell M, (1999) Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol 163, 3771-3777.
19. Kennedy KM, &, Dewhirst MW, (2010) Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation. Future Oncol 6, 127-148.
20. Tesori V, Piscaglia AC, Samengo D, Barba M, Bernardini C, Scatena R, Pontoglio A, Castellini L, Spelbrink JN, Maulucci G, et al,. (2015) The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing. Sci Rep 5, 9149.